Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q3 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $175.8 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold
• Isabella Bank added to Russell 2000 index after Nasdaq listing